Joseph K. Schachle

CIK: 0001145914

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (66.7%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (33.3%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

IRD

Opus Genetics, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (6 total)

IRD
Opus Genetics, Inc.
Oct 23, 2026
Sale(S)
Direct
4.8K shares at avg. $3.56$17K
IRD
Opus Genetics, Inc.
Jul 23, 2026
Sale(S)
Direct
4.6K shares at avg. $2.94$14K
IRD
Opus Genetics, Inc.
Apr 23, 2026
Sale(S)
Direct
4.7K shares at avg. $5.22$25K
IRD
Opus Genetics, Inc.
Mar 16, 2026
Sale(S)
Direct
3.7K shares at avg. $5.25$20K
IRD
Opus Genetics, Inc.
Jan 22, 2026
Award(A)
Direct
250K shares-
IRD
Opus Genetics, Inc.
Mar 13, 2025
Award(A)
Direct
52.5K shares-

		Type	Shares	Price		Ownership
Oct 23, 2026	IRD Opus Genetics, Inc.	Sale(S)	4,767	$3.56	$16,994	Direct
Jul 23, 2026	IRD Opus Genetics, Inc.	Sale(S)	4,644	$2.94	$13,653	Direct
Apr 23, 2026	IRD Opus Genetics, Inc.	Sale(S)	4,697	$5.22	$24,519	Direct
Mar 16, 2026	IRD Opus Genetics, Inc.	Sale(S)	3,719	$5.25	$19,525	Direct
Jan 22, 2026	IRD Opus Genetics, Inc.	Award(A)	250,000	-	$0	Direct
Mar 13, 2025	IRD Opus Genetics, Inc.	Award(A)	52,500	-	-	Direct

1-6 of 6 transactions

About SCHACHLE JOSEPH K

SCHACHLE JOSEPH K (SEC CIK 0001145914) files insider reports with the SEC as Chief Operating Officer of Opus Genetics, Inc. (IRD).

Signal8 holds 6 ownership filings by SCHACHLE JOSEPH K, all Form 4s, filed between Mar 17, 2025 and Oct 27, 2026. Those filings report 6 transactions, from Mar 13, 2025 to Oct 23, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on SCHACHLE JOSEPH K's filings is in DURHAM, NC.

Recent filings by SCHACHLE JOSEPH K

Oct 23, 2026: Open-market sale of IRD shares (Form 4, code S).
Jul 23, 2026: Open-market sale of IRD shares (Form 4, code S).
Apr 23, 2026: Open-market sale of IRD shares (Form 4, code S).
Mar 16, 2026: Open-market sale of IRD shares (Form 4, code S).
Jan 22, 2026: Grant or award of IRD shares (Form 4, code A).

Other insiders filing for Opus Genetics, Inc. (IRD)

YERXA BENJAMIN R, President
Gagnon Robert E., Chief Financial Officer
Magrath George, Chief Executive Officer
Foundation Fighting Blindness Retinal Degeneration Fund, Director
Gallagher Cam, Director
Zaremba Rabourn Amy, Head of Fin. Quality Assurance

How to read Form 4 transaction codes